Navigation Links
Encouraging results in pancreatic cancer research

Researchers at SUNY Downstate Medical Center and the Brooklyn VA Hospital have found that when a human protein, PNC-28, is administered to pancreatic tumor cells in animals, the tumors are destroyed. The research was reported in the October 1st edition of the International Journal of Cancer.

Matthew R. Pincus, MD, PhD, professor of pathology at SUNY Downstate and chairman of pathology and laboratory medicine at the Brooklyn VA, said, "The results are very encouraging. PNC-28 may be an effective agent in treating cancers, especially if delivered directly to the tumor."

PNC-28 is a p53 peptide, a naturally occurring human protein known to suppress tumor growth. The researchers previously found that PNC-28 induces death of a variety of human tumor cell lines, including a pancreatic cancer cell line, while not harming healthy cells.

The research team has now given PNC-28 to laboratory animals to test its ability to block the growth of pancreatic cancer cells. When administered over a two-week period in the peritoneal cavities of mice containing simultaneously transplanted tumors, PNC-28 caused complete destruction of these tumors.

When delivered concurrently with tumor implantation, PNC-28 completely blocked tumor growth during the two-week period of administration and two weeks post-treatment, followed by weak tumor growth that leveled off at low tumor sizes.

In addition, according to Josef Michl, MD, associate professor of pathology at SUNY Downstate, "When administered from a site distant from the tumor, PNC-28 still caused a decrease in tumor size. This tumor growth was significantly slower than growth in the presence of a control peptide."

Dr. Pincus added that this peptide and its parent peptide, called PNC-27, are lethal to a wide variety of human cancer cells, besides pancreatic cancer, including colon, breast, cervical and bone (osteogenic sarcoma) cancers. These peptides kill cancer cells that do not even contain native p53 protein and therefore appear to have a wide applicability in treating a variety of human cancers.
'"/>

Source:SUNY Downstate Medical Center


Related biology news :

1. Gene vaccine for Alzheimers disease shows promising results
2. Roche clinical trial registry and results database launched
3. Diabetic nerve therapy shows striking results
4. Neurologix announces positive results of gene therapy clinical trial in Parkinsons disease
5. New results validating Pall prion reduction filter disclosed at ISBT Congress
6. Tramiprosate (Alzhemed? preclinical results published in Neurobiology of Aging
7. Combination therapy shows promising results in patients with advanced lung cancer
8. Vaccine for brain tumors shows promising results
9. Artificial cornea offers better results for infants, some blind patients
10. The eyes have it -- Autism research yields surprising results
11. UCSF brain tumor vaccine trial shows promising results

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/5/2017)... 2017 Today HYPR Corp. , leading ... component of the HYPR platform is officially FIDO® ... security architecture that empowers biometric authentication across Fortune 500 ... secured over 15 million users across the financial services ... home product suites and physical access represent a growing ...
(Date:4/4/2017)... April 4, 2017   EyeLock LLC , a ... the United States Patent and Trademark Office (USPTO) has ... the linking of an iris image with a face ... represents the company,s 45 th issued patent. ... very timely given the multi-modal biometric capabilities that have ...
(Date:3/30/2017)... 2017  On April 6-7, 2017, Sequencing.com will host ... hackathon at Microsoft,s headquarters in Redmond, ... on developing health and wellness apps that provide a ... Genome is the first hackathon for personal genomics ... companies in the genomics, tech and health industries are ...
Breaking Biology News(10 mins):
(Date:10/12/2017)... ... October 12, 2017 , ... ... States multicenter, prospective clinical study that demonstrates the accuracy of the FebriDx® ... identifying clinically significant acute bacterial and viral respiratory tract infections by testing ...
(Date:10/11/2017)... (PRWEB) , ... October 11, 2017 , ... ... any gene in its endogenous context, enabling overexpression experiments and avoiding the use ... with small RNA guides is transformative for performing systematic gain-of-function studies. , ...
(Date:10/11/2017)... LAGUNA HILLS, Calif. , Oct. 11, 2017 ... London (ICR) and University of ... prognostic tool to risk-stratify patients with multiple myeloma (MM), in ... nine . The University of Leeds ... by Myeloma UK, and ICR will perform the testing services ...
(Date:10/10/2017)... Los Angeles, CA (PRWEB) , ... ... ... Pharmaceuticals, Inc., a development-stage cancer-focused pharmaceutical company advancing targeted antibody-drug conjugate (ADC) ... all uses of targeted HPLN (Hybrid Polymerized Liposomal Nanoparticle), a technology developed ...
Breaking Biology Technology: